Show the dual mechanism of action in tumour and TAMs.
Remind viewers of transcriptional biology.
Illuminate this novel, dual mechanisms of action.
Delivered long-lasting medical education asset.
Content stayed relevant despite varied trial data.
Drove deep clinical engagement with upcoming trial data.

The brief also had a second challenge: much of the audience wouldn't be fluent in transcriptional biology. Fusion built a 3D medical animation that explained the underlying transcription biology clearly and quickly enough to enable viewers to focus on the nuances of the mechanism of action (MoA).
We built the film as a single continuous journey from the lung, through the microenvironment, into the cancer cells and down into the nucleus to help orient the viewer. We then focussed on the specific guanine-containing triplets on the DNA strand where the lurbinectedin binds.
A split screen enabled us to compare the downstream impact with and without the drug. This helped us to show the lack of something (a common challenge we face). In this case, a lack of transcription, which in turn stops protein production.
Once the principles of the impact of inhibiting transcription had been shown, we could then move on to the TAMs within the tumour microenvironment. Here we were able to pull back and show the impact of lurbinectedin on cytokine production without needing to go back into the nucleus of the TAMs
In 2020, Lurbinectedin held FDA accelerated approval for second-line metastatic SCLC, based on data from a Phase 2 trial, conditional on verifying clinical benefit via a confirmatory trial. Jazz Pharmaceuticals and PharmaMar began that trial, LAGOON (Phase 3), in December 2021. This shaped the animation's script: detailed mechanism focus without overstating the clinical story.
LAGOON reported topline results in June 2026, missing its primary endpoint versus chemotherapy in second-line SCLC. Jazz and the FDA are now addressing post-marketing requirements for that indication.
Elsewhere, there is good news: IMforte (Phase 3) showed significant OS/PFS improvements in October 2024 for lurbinectedin plus atezolizumab as first-line maintenance in extensive-stage SCLC, gaining full FDA approval in October 2025.
For us, that's a useful reminder: a video describing the biology, rather than a single indication, tends to stay relevant beyond the context at project kick-off.

Trusted by some of the world's leading pharmaceutical, biotech and medical communications teams - including AstraZeneca, Pfizer, Sanofi, Takeda, Lundbeck and Samsung Biologics.



















